GaetaniLBlennowKCalabresiP, et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry2019; 90: 870–881.
2.
MartinSJMcGlassonSHuntD, et al. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: A meta-analysis of case-control studies. J Neurol Neurosurg Psychiatry. Epub ahead of print 23 May. DOI: 10.1136/jnnp-2018-319190.
3.
VarhaugKNBarroCBjørnevikK, et al. Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm2017; 5: e422.
4.
Van LieverlooGGAWieskeLVerhammeC, et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst2019; 24: 187–194.
5.
ShahimPZetterbergHTegnerY, et al. Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology2017; 88(19): 1788–1794.
6.
FenebergEOecklPSteinackerP, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology2018; 90(1): e22–e30.
7.
MattssonNAndreassonUZetterbergH, et al.; Alzheimer’s Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol2017; 74: 557–566.
8.
GattringerTPinterDEnzingerC, et al. neurofilament light is sensitive to active cerebral small vessel disease. Neurology2017; 89: 2108–2114.
9.
KuhleJBarroCDisantoG, et al. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler2016; 22(12): 1550–1559.
10.
NovakovaLZetterbergHSundstromP, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology2017; 89(22): 2230–2237.
